This report analyzes the disruptive themes that have driven M&A activity in 2024 in the pharma Sector.
Key Highlights
The global pharma sector in 2024 witnessed deals worth $169 billion, a decline of 28% compared to 2023. In terms of deal volume, there was a rise of 18% to record 1,169 M&A deals in 2024. The Pharma sector recorded 48 mega deals (defined as any deal valued at more than $1 billion) in 2024, an increase of 9% compared to 2023.Scope
- This report provides an overview of merger and acquisition activity globally in 2024 in Pharma Sector
- It identifies the themes driving most notable to deals announced in 2024 in the Pharma Sector
Reasons to Buy
- Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&A).
- In this report we have listed down the most notable deals in pharma sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future.
Table of Contents
- Executive Summary
- Review of Pharma M&A Market - 2024
- Top Pharma M&A Deals by Sector - 2024
- Pharma M&A Deals Analysis by Geography - 2024
- Top Themes Driving Pharma M&A Activity - 2024
- Appendix 1: Deal Selection Criteria
- Appendix 2: Top Themes for 2025 in Pharma
- Appendix 3: Thematic Research Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Goldman Sachs Asset Management LP
- F. Hoffmann-La Roche Ltd
- H. Lundbeck AS
- McKesson Corp
- Repligen Corp
- Mankind Pharma Ltd
- Eli Lilly and Co
- Merck & Co
- Biogen
- Novartis
- Ono Pharmaceutical
- Vertex Pharmaceuticals
- Genmab
- Roquette
- AstraZeneca
- Gilead Sciences
- Novo Holdings
- Novartis
- Sanofi
- Johnson & Johnson
- Synthon International Holdings BV
- Poseida Therapeutics Inc
- Longboard Pharmaceuticals Inc
- Community Oncology Revitalization Enterprise Ventures LLC
- Maravai LifeSciences Holdings Inc
- Bharat Serums And Vaccines Ltd
- Morphic Holding Inc
- Eyebiotech
- Human Immunology Biosciences
- Mariana Oncology
- Deciphera Pharmaceuticals
- Alpine Immune Sciences
- ProfoundBio US
- International Flavors & Fragrances
- Fusion Pharmaceuticals
- CymaBay Therapeutics
- Catalent
- MorphoSys
- Inhibrx
- Ambrx Biopharma
